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cellular calcium level and by the proteins intrinsically disordered
endogenous inhibitor, calpastatin, mediated by short conserved
segments: subdomains A–C. The exact binding mode of calpast-
atin to the enzyme has until now been unclear. Our NMR data of
the 141 amino acid long inhibitor, with and without calcium and
calpain, have revealed structural changes and a tripartite binding
mode, in which the disordered inhibitor wraps around, and con-
tacts, the enzyme at three points, facilitated by ﬂexible linkers.
This unprecedented binding mode permits a unique combination
of speciﬁcity, speed and binding strength in regulation.
Structured summary:
MINT-6549073:
Calpain-2 catalytic subunit (uniprotkb:P04632), Calpain-2 cat-
alytic subunit (uniprotkb:P17655) and calpastatin (uni-
protkb:P20810) physically interact (MI:0218) by nuclear
magnetic resonance (MI:0077)
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
Keywords: Intrinsically disordered protein; Supramolecular
complex by NMR; Ligand binding speciﬁcity1. Introduction
Calpain is an intracellular calcium-activated cysteine prote-
ase present in all eukaryotic cells [1]. It controls the activity
of over one hundred target proteins [2] by limited proteolysis
in the regulation of cell division, diﬀerentiation and cell motil-
ity. It occurs together with its endogenous protein inhibitor,Abbreviations: IDP, intrinsically disordered protein; hCSd1, human
calpastatin domain 1; hCSd1 Æ Ca2+, human calpastatin domain 1 with
equivalent CaCl2; complex, human calpastatin domain 1 and m-
calpain complex; cCS, combined chemical shift; A, subdomain A; B,
subdomain B; C, subdomain C
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doi:10.1016/j.febslet.2008.05.032calpastatin [3]. The loss of the control of diﬀerent calpain
forms is implicated in a wide array of diseases ranging from
cataract through muscle dystrophy to diabetes [4]. Despite its
immense biomedical interest, the atomic details of the interac-
tion of calpastatin with calpain are not yet understood. This
paper aims to close this gap.
Calpastatin is an intrinsically disordered [5] protein, com-
posed of an N-terminal L-domain and four equivalent inhibi-
tory domains, each of about 140 amino acids in length [6].
Every inhibitory domain contains three short conserved seg-
ments, termed subdomains, which are primarily responsible
for calpastatin binding to calpain. Subdomain A and C (or
A and C) potentiate inhibition, as they tether the inhibitor to
the enzyme in a calcium-dependent manner, but do not inhibit
enzyme activity on their own [3,7]. The middle segment, B,
binds in the active-site region of the enzyme and carries inhib-
itory potential in itself. In its unbound form, calpastatin lacks
a well-deﬁned structure and falls into the class of intrinsically
disordered proteins, IDPs [8,9].
IDPs play important roles in signal transduction and tran-
scription regulation [10]. Their functions stem from molecular
recognition, in which a part of the IDP becomes ordered in a
process of folding induced by its partner [11], but part of it re-
mains disordered [12]. Uncovering their bound states and the
process of recognition is key to understand IDP action at the
molecular level, as well as to extend the structure–function par-
adigm [13]. Most often, IDPs only bind their partner via a
short recognition element [14], and less frequently by virtue
of two binding elements separated by a disordered linker re-
gion [15]. Only in one case so far has the tripartite binding
of an IDP been described: protein phosphatase 1 (PP1) by
inhibitor-2 (I2) [9,16].
The uniqueness of the interaction of calpastatin with calpain
stems from biochemical data also suggesting its tripartite bind-
ing, with the involvement of the three subdomains and the
intervening disordered linker regions. Due to technical diﬃcul-
ties, however, the structure of the calpain–calpastatin complex
has not yet been solved. The only part of the structure seen is
C, which adopts a helical structure when bound to the small
subunit of calpain [17]. The binding of other segments of cal-
pastatin can only be inferred from the homology of calpastatin
A–C, and the inhibitory action of B. Here we address the
structural state of calpastatin in the bound form by multi-blished by Elsevier B.V. All rights reserved.
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terization of the complexes of IDPs is limited by size, and thus
the longest IDP segment structurally characterized by NMR in
its partner-bound state is 80 amino acids (PDB_entry: 1kxr).
Thus, our attempt to delineate the structural state of the 141
amino acids hCSd1 bound to calpain (MW > 120 kDa) ven-
tures into uncharted territory in terms of size.
D1H and D13C secondary chemical shifts in the presence of
calcium show that the acidic segments on the C-terminal side
of A and C bind Ca2+. Previous models of calpain–calpastatin
binding have suggested that calcium binds calpain, and brings
about its activation by a conformational change [18], which re-
sults in the binding of calpastatin [3]. One study, however, has
suggested that calpastatin can also bind calcium in a way that
may structurally prime it for calpain binding [19]. This novel
ﬁnding suggests that calcium-binding of calpastatin may di-
rectly regulate calpastatin action. In addition, titration of la-
beled calpastatin with calpain has shown that interaction of
the two proteins is limited to three short regions, correspond-
ing to A–C. This is an example of a tripartite binding by an
IDP, which binds its partner via three short recognition ele-
ments separated by two linker regions that remain disordered.
We suggest that this mode of binding, which has so far been
observed in the case of the I2-PP1 complex only, may provide
a unique combination of speciﬁcity and binding strength.2. Materials and methods
2.1. Preparation of calpastatin domain 1
15N- and 15N-, 13C-labeled human calpastatin domain 1 (hCSD1)
(corresponding to A137–K277 of hCSD1, SwissProt P20810) was pro-cCS ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðdðHNHÞSam2  dðHNHÞSam1Þ2 þ 0:17ðdðNNHÞSam2  dðNNHÞSam1Þ20:32ðdðCaÞSam2  dðCaÞSam1Þ2
qduced by using the pEThCSD1 vector (courtesy of Professor Masato-
shi Maki) and the Escherichia coli BL21(DE) strain. Transformed cells
were grown in a minimal medium (5 g glucose, 6 g Na2HPO4, 3 g
KH2PO4, 1 g NH4Cl, 0.5 g NaCl, 0.12 g MgSO4 and 0.01 g CaCl2
per liter of medium) at 37 C to A600 = 0.4–0.5, induced with
0.5 mM isopropyl-b-D-thiogalactopyranoside and grown overnight at
30 C to allow protein expression. The 15N- and 15N–13C-labeled pro-
tein was expressed similarly. The protein was initially puriﬁed as de-
scribed previously [5], and then on a C-18 HPLC column: ﬁnal
purity >98%.
2.2. Preparation of calpain
The BL21(DE3) E. coli strain was transformed with expression vec-
tors coding for the inactive (C105S) m-calpain large and small subunits
provided by Prof. JS. Elce. Cells were grown on NZYM medium (1%
N-Z-Case Plus I (Sigma), 0.5% select yeast extract (Sigma), 0.5% NaCl
and 0.2% MgSO4) containing the appropriate antibiotics (carbenicillin
50 lg ml1, kanamycin 20 lg ml1 at 37 C, 250 rpm until A600 = 0.6–
0.8). Inactive m-calpain was prepared from the bacteria soluble frac-
tion. Expression was induced by 0.4 mM isopropyl-1-thio-b-D-gala-
lctopyranoside at 30 C for 3 h. The culture was cooled and the cells
were collected by centrifugation at 2500 · g, 20 min, 4 C and resus-
pended in lysis buﬀer (50 mM TRIS Æ HCl pH 7.50; 300 mM NaCl;
1 mM EDTA; 5 mM benzamidine; 1 mM phenylmethylsulphonyl-ﬂuo-
ride; 10 mM b-mercaptoethanol). The sample was sonicated for6 · 15 s at 16 lM on ice and the lysate was centrifuged at
100000 · g; 60 min; 4 C. The supernatant (added 10 mM MgCl2 to
block EDTA) was applied to a 5 ml Ni-NTA resin (equilibrated with
50 mM TRIS Æ HCl pH 7.50; 300 mM NaCl). The column was washed
with 15 ml buﬀer (50 mM TRIS Æ HCl pH 7.50; 300 mM NaCl; 15 mM
imidazole; 5 mM benzamidine; 1 mM phenylmethylsulphonyl-ﬂuoride;
10 mM b-mercaptoethanol) and the protein was eluted with imidazole
(250 mM) containing buﬀer. The puriﬁed protein was dialyzed into cal-
pain buﬀer (50 mM TRIS pH 7.50; 150 mM NaCl; 1 mM EDTA;
5 mM benzamidine; 1 mM phenylmethylsulphonyl-ﬂuoride; 10 mM
b-mercaptoethanol) at 4 C. A total of 17 mg calpain was obtained
from 9 dm3 medium. The protein solution was concentrated on Ami-
con Ultra-15 column (Millipore) and dialyzed into the NMR measure
buﬀer (9 mM PIPES pH 6.18; 15 mM NaCl; 10 lM CaCl2; 0.5 mM
benzamidine; 0.1 mM phenylmethylsulphonyl-ﬂuoride).2.3. NMR assignment and relaxation measurements
NMR samples contained 1 mM hCSD1 dissolved in:
Sample 1 (hCSD1 Æ Ca2+): 90% H2O/10% D2O with equivalent CaCl2
(10 lM) and 15 mM NaCl.
Sample 2 (hCSD1): in 90% H2O/10% D2O, with 9 mM PIPES buﬀer
without Ca2+ ion.
All NMR measurements were performed at 300 K. Resonance
assignment of backbone carbon and nitrogen atoms was obtained from
[1H, 15N]-HSQC, HNCA, HN(CO)CA, HNCACB, HN(CO)CACB
and CC(CO)NH type experiments (a total of 2048 complex points in
the 1H- and 128 and 64 complex points in the 15N- and 13C-dimensions
were acquired). Typical spectral widths were 14 ppm in the direct,
32 ppm in the 15N- and 75 ppm in the Ca-, Cb-, and 32 ppm in the
Ca dimension. Data were acquired for hCSD1 Sam1 and last step of
titration of Calpastatin with calpain, by using a spectral width of
10 ppm · 23 ppm (2k · 256 complex points). For NOE enhancement
peak intensities were used.
To characterize the Ca2+ dependence of hCSD1, N-, NH- and Ca
chemical shifts derived from HSQC and HNCA spectra of Sam1 and
Sam2 were used, the combined chemical shifts (cCS) are calculated
as follows:Calpain titration was performed by adding small amounts of calpain
to hCSD1 in Sam2. Calpain stock contained 9 mM PIPES pH 6.18;
15 mM NaCl; 10 lM CaCl2; 0.5 mM benzamidine; 0.1 mM phenylm-
ethylsulphonyl-ﬂuoride. In ﬁrst three titration steps 30 ll aliquots of
calpain stock were added to 330 ll of calpastatin solution and then
60 ll–60 ll in the last two steps. Ligand–substrate ratio in each titra-
tion steps were: 0%, 60%, 120%, 240%, 360% and 460%. During
titration steps with calpain HSQC spectra (Fig. S1) were collected in
each step and peak intensities were used to characterize binding to cal-
pain. The correction for dilution was performed using the signal inten-
sity of K141, residue surely unaﬀected by bounding. Data processed by
NMRPipe [20], resonance assignments completed within Sparky 3.113
[21].3. Results
The high ﬂexibility of the backbone leads to narrower lines,
enabling full resonance assignment of both hCSD1 and
hCSD1 Æ Ca2+ even at a sample concentration <0.5 mM. A to-
tal of 123 spin-systems were identiﬁed for the hCSD1 Æ Ca2+
and 121 for the Ca2+ free form of hCSD1. An unresolved ques-
tion of the calpain–calpastatin system is whether hCSD1 itself
Fig. 1. The eﬀect of Ca2+ on hCSD1 as reported by combined {NNH–HNH–Ca} chemical shifts (see Section 2). The NNH, HNH and Ca data were
recorded for the Ca2+ bond (Sample1) and free (Sample2) states of hCSd1 by using speciﬁc triple resonance NMR experiments. Subdomains A and C
have a tendency to form helix.
Fig. 2. Relative signal intensity changes as recorded by 1H–15N HSQC spectra for the free hCSD1 and hCSD1 gradually titrated with unlabeled
calpain; hCSD1:calpain ratios are 1:0, 1:0.6, 1:1.2, 1:2.4, 1:3.6, 1:4.6. Note that even in the complex, except residues belonging to the core of
subdomains A–C, backbone amide groups of hCSd1 are suﬃciently separated from calpain to relax independent of the supramolecular complex,
preserving their fragmental molecular motion. Interestingly, 1H–15N intensity of A20, D22 and T27 residues of subdomain A and D93, S101, F103 of
subdomain C drops after the second titration step, indicating their tighter binding to calpain.
Table 1
The original and the ﬁne-tuned boundaries of subdomain A–C of hCSd1
Subdomain of hCSD1 A B C
Conserved regions A1–P11 S12–G30 P31–P49 M50–R70 E71–P89 G91–T104 T104–K141
Functional regions A1–K14 S15–G29 G30–K60 R61–L72 L73–P89 I90–T109 A110–K141
NMR signal intensity at 100%a 49.2 2.4 40.6 27.4 50.1 8.6 47.1
aReassessment was completed by using the present hCSd1:calpain complex.
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2152 R. Kiss et al. / FEBS Letters 582 (2008) 2149–2154binds Ca2+. By using CD-spectroscopy, it was shown for a
fragment of C that it binds Ca2+ [19]. The combined chemical
shift (cCS) of each amino acid, except Pro, reveals the residue-
speciﬁc calcium ion binding capacity of hCSd1 (Fig. 1). The
largest shift is detected for E33–E37 positioned right after the
C-terminal part of A, where the COO groups can catch
Ca2+. The glutamic acid-rich region around E119 (C-end of
C) also present signs of Ca2+ binding. In both cases, cCS
changes are either due to the direct inﬂuence of Ca2+ or to
ion-induced structural shifts, i.e. local backbone rearrange-
ment(s), as seen for Y54, Y69 and K60, where direct binding
of Ca2+-ions is less probable.
Based on the estimated rotational diﬀusion correlation time
(sc) of a supramolecular complex of 123 kDa, such as hCSd1/
calpain, no detectable NMR signal is expected. The gradual
titration of the non-selectively 15N-labeled hCSd1 by calpain
has revealed the immediate H-NH signal intensity loss of se-
lected residues. As expected due to the tight binding of calpain
to calpastatin (Kd = 4.5 · 1012), most residues of A and C
bind at high aﬃnity to calpain, and thus lose fragmental back-
bone motion typical of IDPs (Fig. 2). However, other residues
located between the binding sites and preceding A and follow-
ing C preserve their characteristic IDPs motion and still relax
slowly. Thus, they remain detectable by a conventional sensi-
tivity-enhanced HSQC (Figure S1) and no TROSY-type exper-
iment was required. During titration, no signiﬁcant chemical
shift changes were observed, but signals of free hCSD1 are de-
tected only. The absolute signal intensities obtained (Figure
S2), after correction for dilution (see Section 2) (Fig. 2), show
that the boundaries of the binding sites overlap almost per-
fectly with values derived from primary sequence homology
[1] (Table 1). In the absence of Ca2+, no binding of calpastatin
to calpain was seen, i.e. fast exchange was observed in the
whole concentration range (data not shown), in accord with
previous observations (reviewed in Refs. [1,3]).
In general, the most aﬀected signals in the presence of Ca2+
correspond to S15–G29 and I90–T109 residues, typical bound-
aries of A and C. The sCS analysis of hCSd1 in its free form
has revealed for these residues a limited tendency of forming
residual or nascent helices. Detailed analysis of the complex
shows that within these regions G16–L28 in A and G91–F103in
C bind the strongest (Figure S2). At both ends of A and C,
Pro-rich regions are detected (P and P–X–Y–P), most probably
for breaking both helices and for ‘‘elevating’’ the forthcoming
residues, preventing their aspeciﬁc binding to calpain. This
molecular strategy is rather eﬃcient as a few residues away
from the tightly bound S15–G29 and I90–T109, segments relax
independent of the complex, presenting a ﬂexible and frag-
mented backbone motion typical of IDPs. B interacts with cal-
pain, but not exactly in the expected M50–R70 region. The
present titration experiment shows that the interaction is
shifted toward the C-terminus of the molecule to the region
R61–L72, and it is less tight than previously thought. Further-
more, the two residues involved most in the binding of B, Y54
and Y69, bind less tightly than those of A and C (Figs. 2 and
S2).
The het-NOEs of calpain–bound calpastatin were measured
and compared with those of the free hCSD1. Values of selected
and functionally important amino acid (Table 2) show that the
C- and N-terminal residues of the bound calpastatin have al-
most the same ﬂexibility as in the free form. (The NOEs of
the tightly bound residues can not be measured.) However,
R. Kiss et al. / FEBS Letters 582 (2008) 2149–2154 2153in the bound form amino acids of the region between A and C
show a somewhat more ordered state (positive NOEs) than in
free hCSd1.Fig. 3. Schematic representation of calpain: calpastatin complex
depicting the tripartiate binding mode.4. Discussion
Details of the binding mechanism of the IDP calpastatin are
important for a full understanding of the regulation of cal-
cium-activated protease, and to extend our knowledge on the
structure–function relationship of IDPs. These proteins often
carry out their functions by molecular recognition [8,9,11], in
which one or two short regions bind to the partner and become
locally ordered, while ﬂanking regions remain disordered [12].
Our studies throw new light on both calpastatin structure and
the mechanism of binding of calpastatin to calpain.
The ﬁrst intriguing ﬁnding of our studies is that calcium has
a direct eﬀect on calpastatin. It is known, and corroborated by
our observations, that in the absence of calcium calpastatin
does not bind calpain [3,22]. This lack of binding has been
interpreted as a result of the calcium-stimulated conforma-
tional change in calpain, resulting both in activation of the en-
zyme [3] and structural competence with respect to calpastatin
binding. The observation that calpastatin binding requires
lower calcium concentration than enzyme activity [23] has been
explained as suggesting that calpastatin binding shifts the con-
formation of the enzyme to the active form [7]. Our results here
suggest an alternative explanation, namely that A and C of
hCSd1 are responsible for the calcium-induced tethering of
the inhibitor to the enzyme by positioning B next to its active
site [24]. Both A and C are delimited by carboxy-terminal
acidic regions, which directly bind Ca2+ as shown by pro-
nounced changes in sCS. The large negative charge of these re-
gions (E32ETEEE37 and E116KEESTE122) might be neutralized
by Ca2+, which is favorable for the formation of a helix at the
subdomains due to stabilizing the electrostatic dipole that
develops upon helix formation. A similar eﬀect is seen in the
case of helix formation promoted by phosphorylation [25].
As A and C form transient helices in isolation [19], and bind
calpain as amphipathic helices [17], their stabilization by
Ca2+ may be an important mechanistic step in the regulation
of calpastatin action.
The second important result is the binding mode of calpast-
atin to calpain. Prior experiments have suggested that calpast-
atin may only bind via the three subdomains, which can bind
calpain on their own [1,24], and mutations of which results in a
signiﬁcant reduction of inhibitory potential. The exact mode of
binding could not be elucidated, because of the size of the com-
plex (122 kDa) and resistance of calpain and calpain–calpasta-
tin complex to attempts of crystallization in the presence of
Ca2+. The structure of full-length calpain could only be solved
in the absence of calcium, whereas the conformational change
brought about by calcium binding could be inferred from stud-
ies of a truncated version [18]. There have been attempts to
assemble the model of calpastatin binding from separate stud-
ies of its conserved regions, i.e. A and C [26] and B [27]. From
these, the picture has emerged that binding is limited to the
short segments, with the connecting linker regions, which
may even remain disordered in the bound state, of secondary
importance. Our results for the ﬁrst time provide evidence
for this tripartite binding mode. Titration of labeled calpasta-
tin with calpain unequivocally shows that regions S15–G29andI90–T109 (Table 1) bind calpain the strongest, and become fully
immobilized in the complex. The middle region R61–L72 (Table
1) corresponding to B, is also in direct contact with the en-
zyme, but its binding is weaker, transiently sampling unbound
states even in the complex. The linker regions connecting the
subdomains, i.e. G30–K60and L73–P89, remain in a state similar
to the unbound form of high mobility. The terminal regions,
A1–K14 and A110–K141, also remain disordered, not establish-
ing speciﬁc contacts with calpain. Such a binding mode is
rather uncommon for IDPs. Most often, they bind via a short
recognition segment with the ﬂanking region remaining disor-
dered [14]. Sometimes IDPs employ two recognition elements
connected by a linker region, which remains disordered in
the bound state. Such bi-partite binding has been described
for Ste5, Oct1 [15], and bacterial cellulose [28]. Tripartite bind-
ing of an IDP has only been described for I2 binding to PP1
[16], and its general occurrence may be limited by the large
and unfavorable decrease in conﬁgurational entropy, to be
compensated by advantages of excess speciﬁcity.
The present results conﬁrm the previous deﬁnition of subdo-
mains in calpastatin, but reﬁne their exact locations (Table 1).
For the ﬁrst time, subdomains were deﬁned as three well-con-
served regions encoded by separate exons [26,29]. Other se-
quence alignment studies have suggested that A is located
between S12 and G30 and C is between G91 and T104 [3]. These
segments have been suggested as forming a-helices when
bound to calpain, and interference with their helix-forming po-
tential by point mutations does cause a drastic decrease in
binding strength [30]. Our results deﬁne the functional regions
at A as S15–G29, and at C as I90–T109 directly involved in bind-
ing. With respect to B, the borders of the corresponding exon
are D48–A74, and the corresponding peptide shows strong
inhibitory potency [29], though M50–R70 segment is established
as B. Several studies have addressed the core region of inhibi-
tory potential and found that the carboxy-terminal T64–R70
segment is the one primarily responsible for inhibition. In
our experiments the binding of B is not uniform. The edges
(S52–I55 and E62–L72) show stronger binding capacity than
the middle (E56–R61), which might help establish the correct
position of the inhibitory segment.
Our results suggest a tripartite binding mode, in which the
disordered inhibitor wraps around and contacts calpain at
three distinct points (Fig. 3). This binding makes it possible
to combine calcium-dependent recognition by ensuing inhibi-
2154 R. Kiss et al. / FEBS Letters 582 (2008) 2149–2154tion at distinct sites, enabled by the ﬂexibility of the linker re-
gions. Calpastatin is known to be the only inhibitor of calpain
that is highly speciﬁc to the enzyme. We suggest that the ob-
served unprecedented binding mode enables the unique combi-
nation of speciﬁcity, high speed and reversibility in binding
and calpain regulation. Due to the apparent functional bene-
ﬁts, other IDPs may also turn out to utilize similar binding
strategies.
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